

Clinical trials of EGFR inhibitors for lung cancer (metastatic) in first line

TrialResults-center www.trialresultscenter.org

1 TKI

Trial	Treatments	Patients	Trials design and methods
gefitinib vs carboplatin-paclitaxel			
NEJ002 , 2013 n=NA	-	chemo-naive non-small cell lung cancer with sensitive EGFR gene mutations	
IPASS (Mok) , 2009 [NCT00322452] n=NA follow-up:	-	previously untreated patients in East Asia who had advanced pulmonary adenocarcinoma and who were nonsmokers or former light smokers	
gefitinib vs carboplatin/paclitaxel			
IPASS n=NA follow-up:	-	previously untreated never-smokers and light ex-smokers with advanced pulmonary adenocarcinoma	
gefitinib vs gemcitabine and cisplatin			
First Signal n=159/150 follow-up:	gefitinib (250 mg daily) versus GP chemotherapy (gemcitabine 1,250 mg/m ²) on days 1 and 8; cisplatin 80 mg/m ² on day 1 every 3 weeks, for up to nine courses	first-line therapy of never-smokers with adenocarcinoma of the lung	
gefitinib paclitaxel and carboplatin vs paclitaxel and carboplatin			
INTACT 2 , 2004 n=NA follow-up:	gefitinib plus paclitaxel and carboplatin versus paclitaxel 225 mg/m ² and carboplatin area under concentration/time curve of 6 mg/min/mL (day 1 every 3 weeks)	chemotherapy-naive patients with advanced NSCLC	double-blind
osimertinib vs placebo			
FLAURA , 2017 [NCT02296125] n=279/277 follow-up:	osimertinib (AZD9291) (80 mg or 40 mg orally, once daily) versus first-line standard-of-care treatment erlotinib or gefitinib	previously untreated patients with locally advanced or metastatic epidermal growth factor receptor (EGFR) mutationpositive nonsmall cell lung cancer	Parallel groups double-blind
gefitinib + gemcitabine/cisplatin vs placebo + gemcitabine / cisplatin			
INTACT 1. n=NA follow-up:	gefitinib 500 mg/d, gefitinib 250 mg/d, versus placebo	chemotherapy-naive patients with unresectable stage III or IV NSCLC	double blind
gefitinib vs vinorelbine			

continued...

Trial	Treatments	Patients	Trials design and methods
INVITE (Crin) , 2008 [NCT00256711] n=NA	-	chemotherapy-naive elderly patients with advanced non-small-cell lung cancer	

References

NEJ002, 2013:

Inoue A, Kobayashi K, Maemondo M, Sugawara S, Oizumi S, Isobe H, Gemma A, Harada M, Yoshizawa H, Kinoshita I, Fujita Y, Okinaga S, Hirano H, Yoshimori K, Harada T, Saijo Y, Hagiwara K, Morita S, Nukiwa T, , Updated overall survival results from a randomized phase III trial comparing gefitinib with carboplatin-paclitaxel for chemo-naive non-small cell lung cancer with sensitive EGFR gene mutations (NEJ002). *Ann Oncol* 2013;24:54-9. [22967997] [10.1093/annonc/mds214](https://doi.org/10.1093/annonc/mds214)

IPASS (Mok), 2009:

Mok TS, Wu YL, Thongprasert S, Yang CH, Chu DT, Saijo N, Sunpaweravong P, Han B, Margono B, Ichinose Y, Nishiwaki Y, Ohe Y, Yang JJ, Chewaskulyong B, Jiang H, Duffield EL, Watkins CL, Armour AA, Fukuoka M, Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. *N Engl J Med* 2009;361:947-57. [19692680] [10.1056/NEJMoa0810699](https://doi.org/10.1056/NEJMoa0810699)

Wu YL, Saijo N, Thongprasert S, Yang JC, Han B, Margono B, Chewaskulyong B, Sunpaweravong P, Ohe Y, Ichinose Y, Yang JJ, Mok TS, Young H, Haddad V, Ru Efficacy according to blind independent central review: Post-hoc analyses from the phase III, randomized, multicenter, IPASS study of first-line gefitinib versus carboplatin/paclitaxel in Asian patients with EGFR mutation-positive advanced NSCLC. *Lung Cancer* 2017;104:119-125 [28212993]

IPASS, :

Yang JC, Wu YL, Chan V, Kurnianda J, Nakagawa K, Saijo N, Fukuoka M, McWalter G, McCormack R, Mok TS, Epidermal growth factor receptor mutation analysis in previously unanalyzed histology samples and cytology samples from the phase III Iressa Pan-ASia Study (IPASS). *Lung Cancer* 2014;83:174-81. [24361280] [10.1016/j.lungcan.2013.11.021](https://doi.org/10.1016/j.lungcan.2013.11.021)

Wu YL, Chu DT, Han B, Liu X, Zhang L, Zhou C, Liao M, Mok T, Jiang H, Duffield E, Fukuoka M, Phase III, randomized, open-label, first-line study in Asia of gefitinib versus carboplatin/paclitaxel in clinically selected patients with advanced non-small-cell lung cancer: evaluation of patients recruited from mainland China. *Asia Pac J Clin Oncol* 2012;8:232-43. [22897752] [10.1111/j.1743-7563.2012.01518.x](https://doi.org/10.1111/j.1743-7563.2012.01518.x)

Fukuoka M, Wu YL, Thongprasert S, Sunpaweravong P, Leong SS, Sriuranpong V, Chao TY, Nakagawa K, Chu DT, Saijo N, Duffield EL, Rukazenzov Y, Speake G, Jiang H, Armour AA, To KF, Yang JC, Mok TS, Biomarker analyses and final overall survival results from a phase III, randomized, open-label, first-line study of gefitinib versus carboplatin/paclitaxel in clinically selected patients with advanced non-small-cell lung cancer in Asia (IPASS). *J Clin Oncol* 2011;29:2866-74. [21670455] [10.1200/JCO.2010.33.4235](https://doi.org/10.1200/JCO.2010.33.4235)

Mok TS, Wu YL, Thongprasert S, Yang CH, Chu DT, Saijo N, Sunpaweravong P, Han B, Margono B, Ichinose Y, Nishiwaki Y, Ohe Y, Yang JJ, Chewaskulyong B, Jiang H, Duffield EL, Watkins CL, Armour AA, Fukuoka M Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. *N Engl J Med* 2009;361:947-57 [19692680]

First Signal, :

Lee Y, Han JY, Kim HT, Yun T, Lee GK, Kim HY, Lee JS, Impact of EGFR tyrosine kinase inhibitors versus chemotherapy on the development of leptomeningeal metastasis in never smokers with advanced adenocarcinoma of the lung. *J Neurooncol* 2013;115:95-101. [23832498] [10.1007/s11060-013-1199-y](https://doi.org/10.1007/s11060-013-1199-y)

Han JY, Park K, Kim SW, Lee DH, Kim HY, Kim HT, Ahn MJ, Yun T, Ahn JS, Suh C, Lee JS, Yoon SJ, Han JH, Lee JW, Jo SJ, Lee JS, First-SIGNAL: first-line single-agent iressa versus gemcitabine and cisplatin trial in never-smokers with adenocarcinoma of the lung. *J Clin Oncol* 2012;30:1122-8. [22370314] [10.1200/JCO.2011.36.8456](https://doi.org/10.1200/JCO.2011.36.8456)

INTACT 2, 2004:

Herbst RS, Giaccone G, Schiller JH, Natale RB, Miller V, Manegold C, Scagliotti G, Rosell R, Oliff I, Reeves JA, Wolf MK, Krebs AD, Averbuch SD, Ochs JS, Grous J, Fandi A, Johnson DH Gefitinib in combination with paclitaxel and carboplatin in advanced non-small-cell lung cancer: a phase III trial—INTACT 2. *J Clin Oncol* 2004;22:785-94 [14990633]

FLAURA, 2017:

Soria JC, Ohe Y, Vansteenkiste J, Reungwetwattana T, Chewaskulyong B, Lee KH, Dechaphunkul A, Imamura F, Nogami N, Kurata T, Okamoto I, Zhou C, Cho BC, Cheng Y, Cho EK, Voon PJ, Planchard D, Su WC, Gray JE, Lee SM, Hodge R, Marotti M, Rukazenzov Y, Ramali Osimertinib in Untreated EGFR-Mutated Advanced Non-Small-Cell Lung Cancer. *N Engl J Med* 2017;: [29151359]

INTACT 1., :

Ausgem, , Heparin, Unfractionated Heparin, Heparinic Acid, Liquaemin, Sodium Heparin, Heparin Sodium, alpha-Heparin, alpha Heparin, , Labetalol, Labetolol, Albetol, Apo-Labetalol, Apo Labetalol, ApoLabetalol, Dilevalol, Normodyne, Presolol, SCH-19927, SCH 19927, SCH19927, Trandate, AH-5158, AH 5158, AH5158, Labetalol Hydrochloride, , Nadroparine, Fraxiparin, Fraxiparine, CY 216, CY-216, CY216, LMF CY-216, LMF CY 216, LMF CY216, , Nicardipine, Cardene SR, Dagan, Flusemide, Lecibril, Lincil, Loxen, Lucefal, Nicardipine Hydrochloride, Nicardipine LA, Nicardipino Ratiopharm, Nicardipino Seid, Perdipine, Ridene, Y-93, Y 93, Y93, Cardene I.V., Cardene, Vasonase, Antagonil, , Nicorandil, 2-Nicotinamidoethyl Nitrate, 2 Nicotinamidoethyl Nitrate, 2-Nicotinamidethyl Nitrate, 2 Nicotinamidethyl Nitrate, SG-75, SG 75, SG75, Ikorel, Adancor, Dancor, , Nifedipine, Adalat, Bay-1040, Bay 1040, Bay1040, BAY-a-1040, BAY a 1040, BAYa1040, Procardia XL, Nifedipine-GTIS, Nifedipine GTIS, Corinfar, Korinfar, Fenigidin, Nifangin, Nifedipine Monohydrochloride, Procardia, Vascard, Cordipin, Cordipine, , Nitroglycerin, Glyceryl Trinitrate, Nitrolan, Nitrostat, Perlinganit, Susadrin, Sustac, Sustak, Sustonit, Transderm Nitro, Tridil, Trinitrin, Trinitrolong, Anginine, Dynamite, Gilustenon, Nitrangin, Nitro-Bid, Nitro Bid, NitroBid, Nitro-Dur, Nitro Dur, NitroDur, Nitrocard, Nitroderm, Nitroderm TTS, Nitroglyn, Nitrol, Nitrong, Nitrospan, , omapatrilat, Vanlev, BMS 186716, BMS-186716, , Omacor, Lovaza, omega-3 ethyl ester 90, P-OM3 adjunct, , Logiparin, LHN-1, , orlistat, tetrahydrolipstatin, THLP, Alli, Xenical, , Pentoxifylline, Oxpentifylline, BL-191, BL 191, BL191, Trental, Torental, Agapurin, Pentoxil, , Perindopril, Pirindopril, Perstarium, S-9490, S 9490, S9490, S 9490-3, S 9490 3, S 94903, Perindopril Erbumine, , Actos, Practolol, ICI-50172, ICI 50172, ICI50172, Dalzic, Eralzdin Practolol, , Pravastatin, Eptastatin, Liplat, RMS-431, RMS 431, RMS431, SQ-31000, SQ 31000, SQ31000, Vasten, Bristacol, CS-514, CS 514, CS514, Lipemol, Prareduct, Mevalotin, Pravachol, Elisor, Selektine, Pravacol, Pravasin, Lipostat, , prasugrel, CS 747, CS-747, LY 640315, LY640315, LY-640315, Effient, Efient, Probuocol, DH-581, DH 581, DH581, Lorelco, Lurselle, Superlipid, Biphenabid, Panavir, , Propranolol, Propanolol, Avlocardyl, AY-20694, AY 20694, AY20694, Betadren, Dexpropranolol, Inderal, Obsidan, Obzidan, Propranolol Hydrochloride, Rexigen, Anaprilin, Anapriline, Dociton, , Triatec, Altace, Delix, Ramace, Vesdil, Carasel, Acovil, Tritace, Zabien, renolazine, RS 43285-193, Ranexa, RS 43285, RS-43285, , rimonabant, SR141716, SR 141716, Acomplia, Zimulti, SR 141716A, SR141716A, SR-141716A, , Xarelto, BAY 59-7939, , Avandia, Crestor, Tissue Plasminogen Activator, Tissue Activator D-44, Tissue Activator D 44, Tisokinase, Tissue-Type Plasminogen Activator, Tissue Type Plasminogen Activator, TTPA, T-Plasminogen Activator, T Plasminogen Activator, Alteplase, Activase, Actilyse, Lysatec rt-PA, Lysatec rt PA, Lysatec rtPA, , saruplase, prourokinase (enzyme-activating), recombinant unglycosylated single-chain urokinase-type plasminogen activator, pro-urokinase, Rescupase, A-74187, , Zocor, Darob, MJ-1999, MJ 1999, MJ1999, , telmisartan, Micardis, BIBR 277, BIBR-277, Pritor, , tenecteplase, Metalyse, TNKase, Ticlopidine, Ticlopidine Hydrochloride, Ticlodix, Ticlodone, 53-32C, 53 32C, 5332C, Ticlid, , Timolol, Timoptic, Timoptol, Timolol Hemihydrate, Timacar, Timolol Maleate, MK-950, MK 950, MK950, Optimol, Blocadren, , tinzaparin, tinzaparin sodium, Innohep, tirofiban, tirofiban hydrochloride monohydrate, MK 383, MK-383, tirofiban hydrochloride, Aggrastat, Cahill May Roberts brand of tirofiban hydrochloride monohydrate, MSD brand of tirofiban hydrochloride monohydrate, Merck Frosst brand of tirofiban hydrochloride monohydrate, Merck Sharp and Dohme brand of tirofiban hydrochloride monohydrate, Agrastat, Merck brand of tirofiban hydrochloride monohydrate, L 700462, L-700462, , tolvaptan, OPC 41061, OPC-41061, Samsca, , topiramate, Topamax, Epitomax, McN 4853, McN-4853, , trandolapril, Odrik, Udrik, RU 44570, RU44570, RU-44570, Mavik, Gopten, triflusal, Disgren, Centrophne, Vastarel, Idaptan, Trimetazidine Irex, Vasartel, Trimetazidine Dihydrochloride, , Urokinase-Type Plasminogen Activator, Urokinase Type Plasminogen Activator, U-Plasminogen Activator, U Plasminogen Activator, U-PA, Urinary Plasminogen Activator, Urokinase, Renokinase, Abbokinase, Kidney Plasminogen Activator, Single-Chain Urokinase-Type Plasminogen Activator, Single Chain Urokinase Type Plasminogen Activator, , valsartan, Diovan, Tareg, KalpressMiten, Provas, Vals, walsartan, CGP 48933, Nisis, Aventis brand of valsartan, , Verapamil, Iproveratril, Cordilox, Dexverapamil, Falicard, Izoptin, Isoptine, Isoptin, Lekoptin, Verapamil Hydrochloride, Calan, Finoptin, , vesnarinone, OPC 8212, OPC-8212, , Xamoterol, Corwin, ICI-118587, ICI 118587, ICII18587, Xamoterol Fumarate, Xamoterol Hemifumarate, Xamoterol Monohydrobromide, Xamoterol Monohydrochloride, Xamtol, Carwin, Xamoterol Maleate (2:1), , ximelagatran, xi-melagatran, Exanta, H 376 95, H 376-95, , Glucotrol, Warfarin, Coumadine, Apo-Warfarin, Gen-Warfarin, Warfant, Coumadin, Marevan, Warfarin Potassium, Warfarin Sodium, Aldocumar, Tedicumar, , reviparin, reviparine, reviparin-sodium, reviparin sodium, LU 47311, LU-47311, Clivarin, Abbott brand of reviparin-sodium, Clivarine, ICN brand of reviparin-sodium, , Propafenone, Propamerck, Rythmol, Arythmol, Rytmonorm, Norfenon, Pintoform, Propafenon Minden, Rytmo-Puren, Rytmogenat, Baxarytmon, Cuxafenon, Fenoprain, Jutanorm, Nistaken, Prolecofen, , nateglinide, nate-glinide, senaglinide, IPCCPA, AY 4166, AY-4166, DJN 608, Starsis, Starlix, Novartis brand of nateglinide, A 4166, A-4166, Fastic, , Bay K 5552, , Metformin, Dimethylguanylguanidine, Dimethylbiguanidine, Glucophage, , Glyburide, Glybenclamide, Glibenclamide, Diabeta, Euglucon 5, Neogluconin, HB-419, HB 419, HB419, HB-420, HB 420, HB420, Maninil, Micronase, Daonil, Euglucon N, , 4-transhydroxy glyburide, ,

Glucovance, Glyburide-metformin, , Integrilin, Integrelin, reteplase, Retavase, Rapilysin, Betaxolol, SL-75212, SL 75212, SL75212, Betoptic, Betoptima, Betaxolol, Oxodal, ALO-1401-02, ALO 1401 02, ALO140102, Betaxolol, Lipitor, torcetrapib, CP 529414, CP529414, CP-529414, , CYPHER, , XIENCE V, Guidant XIENCE V, Abbott XIENCE V, XIENCE 5, Endeavour, Medtronic Endeavour, albiglutide, , liraglutide, victoza, exenatide, bydureon, exendin-4, Ex4 peptide, exendin 4, AC 2993 LAR, Byetta, AC 2993, , sitagliptin, sitagliptin phosphate, Januvia, MK 0431, MK0431, MK-0431, , Acenocoumarol, Nicoumalone, Acenocoumarin, Synthrome, Synthrom, Syncoumar, Syncumar, Sinkumar, Sintrom, Mini-Sintrom, Mini Sintrom, MiniSintrom, , Tissue Plasminogen Activator, Tissue Activator D-44, Tissue Activator D 44, Tisokinase, Tissue-Type Plasminogen Activator, Tissue Type Plasminogen Activator, TTPA, T-Plasminogen Activator, T Plasminogen Activator, Alteplase, Activase, Actilyse, Lysatec rt-PA, Lysatec rt PA, Lysatec rtPA, , Bepridil Monohydrochloride, Vascor, Bedapin, CERM-1978, CERM 1978, CERM1978, 1978-CERM, 1978 CERM, 1978CERM, Cordium, Unicordium, Bepadin, , Ethyl Chlorophenoxyisobutyrate, Atromid, Atromid S, Mischleron, Miskleron, Athromidin, , elinogrel, PRT 060128, PRT060128, PRT-060128, , Brain Natriuretic Peptide, BNP-32, BNP 32, Nesiritide, B-Type Natriuretic Peptide, BNP Gene Product, Type-B Natriuretic Peptide, Type B Natriuretic Peptide, Natriuretic Peptide Type-B, Natriuretic Peptide Type B, Natriuretic Factor-32, Natriuretic Factor 32, Brain Natriuretic Peptide-32, Brain Natriuretic Peptide 32, Natrecor, , Phenindione, Phenylindanedione, Phenylene, Pindione, Fenilin, Dindevan, , repa-glinide, AG-EE 388 ZW, NovoNorm, GlucoNorm, Prandin, AG-EE 388, AG-EE 623 ZW, , Brilique, Brilinta, AZD 6140, AZD6140, AZD-6140, zofenopril, Zofenil, Zofil, SQ 26900, SQ-26900, SQ 26991, SQ-26991, , SQ 26703, zofenopril-SH, zofenopril-SH cpd with arginine, , MK 0859, MK0859, MK-0859, , PRT054021, , buflomedil, buflomedil, Buflor AbZ, AbZ brand of buflomedil hydrochloride, Buflor-POS, Ursapharm brand of buflomedil hydrochloride, Buflor-Puren, Alpharma brand of buflomedil hydrochloride, Buflorhexal, Hexal brand of buflomedil hydrochloride, Buflomedil Heumann, Heumann brand of buflomedil hydrochloride, buflomedil hydrochloride, Buflomedil Lindo, Lindopharm brand of buflomedil hydrochloride, buflomedil pyridoxal phosphate, Buflomedil Stada, Stadapharm brand of buflomedil hydrochloride, buflomedil von ct, ct-Arzneimittel brand of buflomedil hydrochloride, Buflomedil-ratiopharm, ratiopharm brand of buflomedil hydrochloride, Fonzylane, Lafon brand of buflomedil hydrochloride, LL 1656, Loftyl, Bufedil, Lofton, Abbott brand of buflomedil hydrochloride, Sinosis, Hosbon brand of buflomedil hydrochloride, Buflor 1A Pharma, 1A brand of buflomedil hydrochloride, , Folic Acid, Vitamin M, Pteroylglutamic Acid, Folate, Folvite, Folacin, , Hydrochlorothiazide, HCTZ, Dichlothiazide, Dihydrochlorothiazide, HydroDIURIL, Oretic, Sectrazide, Esidrix, Esidrex, Hypothiazide, , inogatran, N-(2-(2-(((3-((aminoiminomethyl)amino)propyl)amino)carbonyl)-1-piperidinyl)-1-(cyclohexylmethyl)-2-oxo-ethyl)glycine, H 314-27, H314-27, H-314-27, , voglibose, Basen, , Trepidil, Trapymin, Rocornal, , desdiethyltrapidil, N-dediethyltrapidil, desdiethyl-trapidil, , certoparin, certoparin sodium, Mono-Embolex, Novartis brand of certoparin sodium, Alphaparin, Grifols brand of certoparin sodium, , glimepiride, glymepiride, HOE 490, HOE-490, Roname, Amaryl, Amarel, hydroxylimepiride, hydroxy-glimepiride, , Linagliptin, Tradjenta, BI 1356, BI1356, BI-1356, , taspoglutide, , miti-glinide, KAD 1229, KAD-1229, , transcatheter aortic valve implantation, , sibutramine, Meridia, mono-desmethyilsibutramine, BTS 54 524, BTS-54524, BTS 54524, Reductil, di-desmethyilsibutramine, didesmethylsibutramine, (R)-DDMS, sibutramine hydrochloride, , saxagliptin, Onglyza, BMS 477118, BMS477118, BMS-477118, , eplerenon, Inspra, CGP 060536B, CGP060536B, CGP-060536B, Tekturna, SPP100, , SYR 322, SYR322, SYR-322, , benfluramate, benfluorex maleate, SE 780, 780 SE, JP 992, Mediator trade name of benfluorex hydrochloride, Biopharma brand of benfluorex hydrochloride, Modulator trade name of benfluorex hydrochloride, Servier brand of benfluorex hydrochloride, S 780, benfluorex hydrochloride, 1-(2-(trifluoromethylphenyl)-2-(benzoyloxyethyl)aminopropane HCl, , Coronary Artery Bypass, Coronary Artery Bypasses, Coronary Artery Bypass Surgery, Aortocoronary Bypass, Aortocoronary Bypasses, Coronary Artery Bypass Grafting, CABG, AR C69931MX, AR-C69931MX, , Carotid Endarterectomy, Carotid Endarterectomies, , Chlortalidone, Phthalamudine, Chlorphthalidolone, Oxodoline, Thalitone, Hygroton, , dofetilide, 1-(4-methanesulfonamidophenoxy)-2-(N-(4-methanesulfonamidophenethyl)-N-methylamine)ethane, 1-MSPMPE, Tikosyn, UK 68798, , docetaxol, Taxoltere metro, Taxotere, NSC 628503, RP 56976, RP-56976, ebselen, PZ 51, PZ-51, RP 60931, DR 3305, DR-3305, , Fenoximone, Perfan, MDL 19438, MDL-17043, MDL 17043, MDL17043, , enoximone sulfoxide, MDL 17043 sulfoxide, , Exercise Therapy, Exercise Therapies, , Gene Therapy, DNA Therapy, Somatic Gene Therapy, , Ginkgo biloba, Ginkgo bilobas, Ginko, Ginkos, Ginkgo, Ginkgos, Gingko, Gingkos, Maidenhair Tree, Maidenhair Trees, Ginkgo biloba, Ginkgo bilobas, Ginkgophyta, Ginkgophytas, , Lacipil, Lacimen, Caldine, Motens, GR 43659X, GR-43659X, , olmesartan medoxomil, CS 866, CS-866, Votum, Benicar, Olmetec, , h5G1.1-scFv, pexelizumab, , Amitriptyline, Tryptine, Amineurin, Amitrip, Amitriptylin Beta, Amitriptylin Desitin, Amitriptylin RPh, Amitriptylin-Neuraxpharm, Amitriptylin Neuraxpharm, Amitriptyline Hydrochloride, Amitrol, Anapsique, Apo-Amitriptyline, Apo Amitriptyline, Damilen, Domical, Laroxyl, Lentizol, Novoprotect, Saroten, Sarotex, Syneudon, Triptafen, Endep, Tryptizol, Elavil, Tryptanol, , Dalteparin, Tedelparin, Kabi-2165, Kabi 2165, Kabi2165, Fragmin, Fragmine, Dalteparin Sodium, FR-860, FR 860, FR860, , efgatran,

Me-Phe-Pro-Arg-H, D-methyl-phenylalanyl-prolyl-arginal, GYKI 14766, GYKI-14766, LY 294468, LY-294468, efegatran sulfate, , etofibrate, Lipo-Merz, Merz brand of etofibrate, Tricerol, Armstrong brand of etofibrate, etofibrate hydrochloride, , simendan, OR-1855, Simadax, dextrosimendan, OR 1259, OR-1259, , ZP10A peptide, AVE 0010, AVE0010, AVE-0010, Lixisenatide, AQVE-10010, , primary ballon angioplasty, primary PTCA, vildagliptin, (2S)-(((3-hydroxyadamantan-1-yl)amino)acetyl)pyrrolidine-2-carbonitrile, NVP-LAF237, Galvus, , Gliclazide, Glyclazide, Gliklazid, Diamicron, S-1702, S 1702, S1702, S-852, S 852, S852, Diaglyk, Gen-Gliclazide, Gen Gliclazide, Glyade, Novo-Gliclazide, Novo Gliclazide, Diaikron, Diabrezide, , Qnexa, Zontivity, SCH 530348, SCH530348, SCH-530348, , MDX-1106, ONO-4538, BMS-936558, Opdivo, lambrolizumab, Keytruda, MK-3475, , MDX-CTLA-4, Yervoy, DX 010, MDX010, MDX-010, , Iressa, ZD1839, ZD 1839, , Anzatax, NSC-125973, NSC 125973, NSC125973, Taxol, Taxol A, Bris Taxol, Paxene, Praxel, 7-epi-Taxol, 7 epi Taxol, Onxol, SDZ RAD, SDZ-RAD, 40-O-(2-hydroxyethyl)-rapamycin, RAD 001, RAD001, Afinitor, Certican, , pertuzumab, Perjeta, Omnitarg, ado-trastuzumab emtansine, trastuzumab-DM1, trastuzumab-DM1 conjugate, T-DM1 cpd, trastuzumab emtansine, huN901-DM1, Kadcylla, Avastin, , gemcitabine, dFdCyd, 2'-deoxy-2'-difluorocytidine, gemcitabine hydrochloride, LY 188011, LY-188011, Gemzar, , Toremifene, Toremifene Citrate, Toremifene Citrate (1:1), Fareston, FC-1157a, FC 1157a, FC1157a, , Xeloda, , Cisplatin, cis-Diamminedichloroplatinum(II), Platinum Diamminodichloride, cis-Platinum, cis Platinum, Dichlorodiammineplatinum, cis-Diamminedichloroplatinum, cis Diamminedichloroplatinum, cis-Dichlorodiammineplatinum(II), NSC-119875, Platino, Platinol, Biocisplatinum, Platidium, , ICI 182780, ICI-182780, ZM 182780, ZM-182780, Faslodex, , palbociclib, Ibrance, PD 0332991, PD0332991, PD-0332991, anastrozole, anastrazole, ICI D1033, ZD-1033, Zeneca ZD 1033, ZD1033, Arimidex, letrozole, Femara, Fmara, CGS 20267, CGS-20267, Aminoglutethimide, Cytadren, Orimeten, formestane, 4-hydroxyandrostenedione, 4-OHA, Lentaron, CGP-32349, CGP 32 349, CGP 32349, , exemestane, FCE 24304, FCE-24304, Aromasil, Aromasin, Aromasine, , Fadrozole, CGS-16949A, CGS 16949A, CGS16949A, Fadrozole Hydrochloride, Fadrozole Mono-hydrochloride, CGS 020286A, CGS020286A, CGS-020286A, FAD 286, FAD286, FAD-286, , Tamoxifen, ICI-47699, ICI 47699, ICI47699, Nolvadex, Novaldex, Tamoxifen Citrate, Tomaxithen, Zitazonium, ICI-46474, ICI 46474, ICI46474, Soltamox, ixabepilone, BMS247550, BMS-247550, BMS 247550, Herceptin, Torisel, CCI 779, CCI-779, , alirocumab, REGN727 monoclonal antibody, monoclonal antibody REGN727, SAR236553, Praluent, , AMG 145, evolocumab, AMG-145, Repatha, Medroxyprogesterone Acetate, Medroxyprogesterone 17-Acetate, Medroxyprogesterone 17 Acetate, Depo-Medroxyprogesterone Acetate, Depo Medroxyprogesterone Acetate, 6-alpha-Methyl-17alpha-hydroxyprogesterone Acetate, 6 alpha Methyl 17alpha hydroxyprogesterone Acetate, Curretab, Cycrin, Depo-Provera, Depo Provera, DepoProvera, Farlutal, Perlutex, Provera, Veramix, Clinovir, Gestapuram, sorafenib, sorafenib N-oxide, 4-(4-(3-(4-chloro-3-trifluoromethylphenyl)ureido)phenoxy)pyridine-2-carboxylic acid methyamide-4-methylbenzenesulfonate, BAY 545-9085, BAY-545-9085, sorafenib tosylate, BAY 43-9006, Nexavar, , entinostat, SNDX-275, MS 27-275, MS-275, MS 275, MS-27-275, B 1939, B-1939, E 7389, E-7389, Halaven, NSC 707389, NSC707389, NSC-707389, B 1793, B-1793, ER-086526, ER086526, ER 086526, ER-86526, , Abraxane, vinorelbine, 5'-nor-anhydrovinblastine, Navelbine, vinorelbine tartrate, KW 2307, KW-2307, , intensive treatment, tighter control of blood pressure, low target blood pressure, strict blood pressure control, intensified blood-pressure control, IMC C225, IMC-C225, Mab C225, C225, Erbitux, , Tarceva, CP 358774, CP-358774, OSI-774, Inlyta, AG 013736, AG013736, AG-013736, , TKI 258, TKI258, TKI-258, dovitinib, CHIR 258, CHIR258, CHIR-258, , GW 786034B, GW786034B, GW-786034B, GW 780604, GW780604, GW-780604, Votrient, , Sutent, SU 11248, SU11248, SU-11248, SU011248, SU 011248, SU-011248, , D2E7 Antibody, Humira, Cimzia, Cimzias, CDP870, CDP870s, CDP 870, CDP 870s, , TNF Receptor Type II-IgG Fusion Protein, TNF Receptor Type II IgG Fusion Protein, Enbrel, Recombinant Human Dimeric TNF Receptor Type II-IgG Fusion Protein, Recombinant Human Dimeric TNF Receptor Type II IgG Fusion Protein, TNFR-Fc Fusion Protein, TNFR Fc Fusion Protein, TNR-001, TNR001, TNR 001, TNT Receptor Fusion Protein, TNTR-Fc, , Simponi, , Mab cA2, Monoclonal Antibody cA2, Remicade, , Interleukin 1 Receptor Antagonist Protein, Urine-Derived IL1 Inhibitor, Urine Derived IL1 Inhibitor, IL1 Febrile Inhibitor, Urine IL-1 Inhibitor, IL-1Ra, Anril, Kineret, Anakinra, , tocilizumab, atlizumab, Actemra, , Rituxan, MabThera, Zytux, Rituximab, Rituximab CD20 Antibody, Mabthera, IDEC-C2B8 Antibody, IDEC C2B8 Antibody, IDECC2B8 Antibody, IDEC-C2B8, IDEC C2B8, IDECC2B8, GP2013, Rituxan, , tasocitinib, tofacitinib citrate, Xeljanz, CP690550, CP-690550, CP 690550, , durvalumab, Imfinzi, MPDL3280A, Tecentriq, RG7446, RG-7446, , MTA, Pemetrexed Disodium, LY 231514, LY231514, LY-231514, Alimta, , rolofylline, KW 3902, KW-3902, MK 7418, MK7418, MK-7418, , BG 9928, BG-9928, BG9928, BIO 4683, BIO4683, BIO-4683, BIO 5770, BIO5770, BIO-5770, BIO 8170, BIO8170, BIO-8170, BIO 9002, BIO9002, BIO-9002, tonapofylline, BIO 7505, BIO7505, BIO-7505, , Invokana, , BI 10773, BI10773, BI-10773, Jardiance, , dapagliflozin, forxiga, BMS 512148, BMS512148, BMS-512148, , avelumab, MSB0010718C, , Xalkori, PF-02341066, PF02341066, PF 02341066, , BAY 94-8862, finerenone, , AZD 2281, AZD2281, AZD-2281, AZD221, Lynparza, , 2-(4-(piperidin-3-yl)phenyl)-2H-indazole-7-carboxamide, niraparib hydrochloride, MK 4827, MK4827, MK-4827, , BMN 673, , 2-((R)-2-methylpyrrolidin-2-yl)-

1H-benzimidazole-4-carboxamide, 2-(2-methylpyrrolidin-2-yl)-1H-benzimidazole-4-carboxamide, ABT 888, ABT888, ABT-888, , bococizumab, , CH5424802, alectinib, RO5424802, , ceritinib, Zykadia, LDK378, , AP26113, brigatinib, , caprelsa, ZD 6474, ZD6474, ZD-6474, vandetanib, Zactima, , imetelstat, motesanib, motesanib diphosphate, AMG 706, AMG706, AMG-706, , aflibercept, VEGF Trap-Eye, VEGF Trap - regeneron, VEGF-Trap, AVE 005, AVE005, AVE-005, Zaltrap, ZIV-aflibercept, AVE 0005, AVE0005, AVE-0005, eylea, , osimertinib, Tagrisso, , rucaparib, AG 014699, AG014699, AG-014699, PF-01367338, , cabozantinib, Cometriq, XL 184, XL184 cpd, XL-184, BMS 907351, BMS907351, BMS-907351, , abemaciclib, LY2835210, LY2385219, Verzenio, ribociclib, LEE011, , vemurafenib, Zelboraf, R05185426, RG7204, RG-7204, PLX4032, PLX 4032, , ticilimumab, CP 675, P675 cpd, CP-675, CP-675,206, CP-675206, CP675206, CP 675206, , carfilzomib, Kyprolis,

2 About TrialResults-center.org

TrialResults-center is an innovative knowledge database that collects the results of RCTs and provides dynamic interactive systematic reviews and meta-analysis in the field of all major heart and vessels diseases.

The TrialResults-center database provides a unique view of the treatment efficacy based on all data provided directly from clinical trial results, offering a valuable alternative to personal bibliographic search, published meta-analysis, etc. Furthermore, it would allow comparing easily the various concurrent therapeutic for the same clinical condition.

Rigorous meta-analysis method is used to populate TrialResults-center: widespread search of published and non published trials, study selection using pre-specified criteria, data extraction using standard form.

TrialResults-center is continually updated on a weekly basis. We continually search all new results (whatever their publication channel) and these news results are immediately added to the database with a maximum of 1 week.

TrialResults-center is non-profit and self-funded.